Table 3 Potencies of nutlin-3a and navtemadlin measured under normoxic and hypoxic conditions in cancer cell lines expressing wild-type p53.

From: MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia

Cell line

nutlin-3a

navtemadlin

Normoxia IC50 (95% CI)

Hypoxia IC50 (95% CI)

Padj

Normoxia IC50 (95% CI)

Hypoxia IC50 (95% CI)

Padj

HCT116 p53+/+

1.6 (1.3–1.9)

1.4 (1.1–1.6)

0.99

0.3 (0.3–0.4)

0.3 (0.2–0.4)

0.99

MCF7

1.8 (0.9–2.8)

2.7 (0–8.8)

0.96

0.2 (0.2–0.3)

0.3 (0.1–0.4)

0.95

B16-F10 p53+/+

8.6 (6.9–10.3)

6.9 (3.2–10.2)

0.74

1.4 (1.2–1.5)

1.3 (1.0–1.7)

0.96

  1. Potency was calculated as the concentration of drug that reduced cell growth by 50% of the untreated control (IC50), as measured by a cellular viability assay. Cellular confluence was measured after 72 h of exposure to 10 drug concentrations.
  2. CI confidence interval.
Back to article page